The Hidden Giants of Healthcare Inflation: Why Hospital Prices Escape the Public Scrutiny Given to Drugs

By Investigative Desk
Published: July 16, 2026

In the ongoing national debate over the escalating cost of medical care in the United States, one narrative has dominated the headlines for decades: the predatory pricing of pharmaceutical companies. From the outrage surrounding insulin costs to the high-profile legislative battles over drug price negotiation, the American public has been trained to view the pharmacy counter as the primary engine of healthcare inflation.

However, a critical analysis published in the JAMA Health Forum by Larry Levitt, Executive Vice President for Health Policy at KFF, challenges this conventional wisdom. While drug prices are undeniably high, the real financial behemoth driving the exhaustion of national health budgets is the hospital sector. Between 2022 and 2024, hospitals accounted for a staggering 40% of the growth in national health spending, yet they remain largely shielded from the intense public and political scrutiny directed at the pharmaceutical industry.

Main Facts: The Disproportionate Burden of Hospital Costs

The fundamental reality of U.S. healthcare economics is that spending is not distributed evenly across sectors. While the cost of a single specialized medication can be thousands of dollars, the cumulative cost of hospital stays, facility fees, and emergency room visits represents a much larger share of the nation’s health expenditure.

According to data analyzed by KFF, hospital services comprise the largest single category of personal health spending. While pharmaceutical costs are highly visible—often paid directly by consumers at the counter or through easily identifiable copays—hospital costs are frequently buried within the complex "black box" of private insurance negotiations. This lack of transparency has allowed hospital systems to consolidate, expand their market power, and raise prices with relatively little resistance compared to the public outcry aimed at drug manufacturers.

Chronology of the Divergent Narratives

To understand why the public discourse is so skewed, one must look at the historical trajectory of healthcare politics:

The 1990s and 2000s: The pharmaceutical industry became the primary target for consumer advocacy groups. High-profile drug advertisements and the introduction of expensive new biologics made drugs a tangible, easily understood villain for patients facing high out-of-pocket costs.
The 2010s: The Affordable Care Act (ACA) focused heavily on insurance coverage and access. During this time, hospitals were often viewed as partners in the expansion of care, rather than the primary drivers of cost.
2020–2022 (The Pandemic Era): Hospitals were widely lauded as "heroes" during the COVID-19 pandemic. This reputation cemented a protective wall around the industry, making it politically difficult for policymakers to criticize hospital billing practices.
2023–2026 (The Current Crisis): With national health spending reaching record highs post-pandemic, researchers have begun to pull back the curtain on hospital pricing. The data reveals that since 2019, hospital prices for private insurance have risen at a rate significantly faster than Medicare, suggesting that the industry is leveraging its market dominance to inflate costs.

Supporting Data: Why Hospitals Escape the Spotlight

Larry Levitt identifies four primary reasons why the public focus remains laser-focused on drugs while hospital spending continues to soar unchecked:

1. Visibility and Point-of-Sale Pain

Pharmaceutical costs are highly transparent. A patient walks into a pharmacy, is told a drug costs $500, and experiences immediate, visceral "sticker shock." In contrast, hospital billing is famously opaque. Most patients do not know the price of a procedure until weeks after the fact, and the costs are often filtered through insurance deductibles and coinsurance, masking the true underlying price being charged by the hospital.

2. Market Consolidation and "Too Big to Fail"

The hospital sector has undergone a massive wave of consolidation. Large hospital systems have acquired smaller community clinics and independent practices, creating regional monopolies. This consolidation grants these systems immense bargaining power against insurers. Unlike drug companies, which are often national or global entities, hospitals are localized community staples, making it politically hazardous for local or state legislators to challenge their pricing power.

3. The "Hero" Narrative

As previously noted, the pandemic transformed the public image of hospitals. It is politically challenging to argue for the regulation of hospital prices when the public perceives those institutions as essential lifelines. The pharmaceutical industry, conversely, has never enjoyed such a broad-based, sentimental public image, making it an easy target for politicians seeking to score points with voters.

4. The Complexity of "Facility Fees"

Hospitals have increasingly shifted toward charging "facility fees" for services performed in outpatient settings—services that could be performed in a doctor’s office at a fraction of the cost. Because these fees are often billed as part of a larger medical visit, they are difficult for the average patient to isolate, making it harder for the public to organize against the specific practice of price-gouging through site-of-service differentials.

Official Responses and Industry Defense

The hospital lobby, represented by powerful organizations like the American Hospital Association (AHA), consistently argues that high costs are a function of the rising complexity of care, the need to maintain emergency readiness, and the systemic underpayment by government programs like Medicaid.

"Hospitals are operating on razor-thin margins," a spokesperson for a national hospital network recently stated in response to inquiries regarding price growth. "The increase in spending is a reflection of the rising cost of labor, medical supplies, and the administrative burden of complying with federal regulations."

However, independent economic analysts argue that these claims are often overstated. Data indicates that while labor costs have risen, the price increases for private insurance have significantly outpaced inflation, suggesting that hospital systems are using their market power to pad their bottom lines rather than simply covering rising operational costs.

Implications for Future Policy

If the goal of the U.S. healthcare system is to achieve true affordability, policymakers cannot continue to ignore the hospital sector. The implications of this silence are profound:

Insurance Premium Spikes: Because hospitals account for the largest share of the premium dollar, as long as hospital prices continue to rise, insurance premiums will continue to climb, forcing employers to shift more of the cost onto workers.
The Erosion of Access: Ironically, by driving up the total cost of care, hospitals may be making themselves inaccessible to the very patients they serve. High deductibles, driven by high hospital costs, are leading to "medical bankruptcy" and the avoidance of necessary care.
The Need for Price Transparency: The next phase of healthcare reform must go beyond drug price negotiation. Policymakers are increasingly discussing "site-neutral" payment policies, which would prevent hospitals from charging higher rates for services simply because they are performed in a hospital-owned facility.

Conclusion

Larry Levitt’s analysis serves as a wake-up call. While the pharmaceutical industry has been the traditional villain in the story of healthcare costs, the data suggests that the true architect of the current crisis is a hospital system that has grown too powerful and too opaque.

To address the rising tide of healthcare spending, the political conversation must shift. It is time for legislators, consumer advocates, and the public to demand the same level of transparency and accountability from hospital systems that they have rightfully demanded from pharmaceutical companies. Until the "hospital price" conversation moves from the shadows of insurance contracts into the light of public policy, the dream of affordable healthcare for all Americans will remain out of reach.